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P1 - APPLICATION OF ARTEFICIAL INTELLIGENCE IN PERSONALIZED 
TREATMENT OF ONCOLOGY PATIENTS
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1Varaždin General Hospital, Varaždin, Croatia  
2Pula General Hospital, Pula, Croatia
Objective: Oncology is one of the most dynamic branches of medicine. As a result of numerous 
oncology studies, there has been a significant increase in scientific and clinical data that the human brain 
cannot store. Advances in artificial intelligence (AI) technology have led to its rapid clinical application. In 
this paper, we wanted to see the role of the use of artificial intelligence (AI) in oncology.
Methods: We conducted a comprehensive database search (Pub Med, MEDLINE, and Google Scholar) 
using the keywords: artificial intelligence, deep learning, machine learning, oncology, personalized medi-
cine. We supplemented the database search with reference list checks. The primary objectives were clarity 
and innovation regarding the use of artificial intelligence in oncology and the ability to apply the results 
in everyday clinical work. Exclusion criteria were: not about cancer and AI, lack of relevance after review-
ing of the title and abstract, papers not written in English, publications before 2015, studies not reviewed, 
not applicable in everyday clinical work. From a large number of articles available to us, we have selected 
review articles and results of clinical trials according to their clarity and innovation in terms of the use of 
artificial intelligence in oncology.
Results: The possibilities of using artificial intelligence in oncology are innumerable. It can be used 
for diagnostic purposes (screening programs, histopathology, and molecular diagnostics), therapeutic 
purposes (personalized treatment, anticipation of treatment side effects and response to therapy, treat-
ment decisions), as well as for prognostic purposes (risk stratification, survival prediction, monitoring). 
For example, the use of stored mammograms can help us identify breast cancer, the use of stored digital 
pathology images can help us diagnose cancer and the analysis of stored dermoscopy images can identify 
skin lesions, such as melanoma. In general, we can say that AI is already used to perform various tasks in 
oncology at a level equal to or sometimes greater than the level of clinicians. The goal of modern oncology 
is personalized treatment. Given the large amount of data that oncologists are daily exposed if we want to 
personalize oncology, we need the help of AI. Namely, the prerequisite for personalized treatment is 
knowledge of the genomic data of the tumour, i.e. whether there are possible genomic mutations in the 
tumour as target points of oncological treatment. Hundreds of thousands of articles are published annu-
ally on genomic mutations and cancer. Therefore, databases are being created that aim to help clinicians 
(e.g. COSMIC, ExPecto, The Cancer Imaging Archive [http://www.cancerimagingarchive.net], and 
Genomic Data Commons Data Portal [https://portal.gdc. rak.gov]). Genomic tests in oncology also play an 
important role. Thus, only in 2017., the FDA approved several such tests (Oncotype Dx, Praxis Extended 
RAS Panel, MSK-IMPACT, and FoundationOne CDx). They help us predict the prognosis of cancer so we 
can avoid over-treating cancer patients. Although the application of AI in oncology seems very complex 
and still inaccessible to all oncology centres, given the required infrastructure and skills of clinicians, some 
segments of AI can already be used in everyday clinical practice. Thus, AI can help us make decisions 
about cancer treatment. Namely, decisions on oncology treatment are based on the assessment of the 
patient’s clinical condition (PS = performance status). It is a subjective assessment made by the clinician by 
observing the patient’s condition and based on data obtained in conversation with the patient. An objec-
tive assessment of the patient’s clinical condition (PS) is difficult because patients spend most of their time 
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outside the hospital. But objective real-time activity data that we can collect with physical activity tracking 
devices, such as smartphones or smartwatches, can help. A prospective study by Gresham et al (2018) 
showed us that monitoring patient activity (steps, distance, stairs) can help not only in assessing the clini-
cal condition of patients with metastatic cancer but also in assessing clinical outcomes (side effects, hospi-
talization, survival). These findings should be confirmed in larger, randomized trials.
Conclusions: The application of AI in clinical practice presents new challenges for clinicians. Namely, 
in the era of evidence-based and patient-centered medicine, they will have to master statistical as well as 
computer skills, in addition to clinical ones. Therefore, it is necessary to start educating future doctors 
about the importance of artificial intelligence as soon as possible.
Keywords: artificial intelligence, oncology, personalized medicine
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P2 - APPLICATION OF CHEMOTHERAPY VIA ELASTOMERIC PUMP  
IN AN OUTPATIENT SETTING: PATIENT SATISFACTION SURVEY
Jurica Vrbanec, Lidija Kocić, Dragan Trivanović
Medical Oncology, Pula General Hospital, Pula, Croatia
The use of elastomeric pumps to administer chemotherapy in protocols that require 48 hours con-
tinuous infusion was recently introduced in Pula General Hospital. This allows the application to be 
administered at hospital day center and continued at patients home as opposed to in hospital stay. We 
conducted a research among patients who had the experience of receiving chemotherapy via an elasto-
meric pump and also used to receive the same therapeutic protocol while admitted in our oncology depart-
ment. We carried out a telephone survey on 19 patients who answered a questionnaire prepared for this 
research. One subject received application via the peripheral venous route, and the other eighteen used a 
central venous port catheter. There were ten questions prompting general satisfaction and perceived safety 
during the use of elastomeric pumps, as well as comparing the experience of receiving the chemotherapy 
at home with being admitted in hospital. The responses in the survey indicate that application of chemo-
therapy at home via the elastomeric pump improves some aspects of daily life. Specifically the most pro-
nounced improvements were reported in the quality of social relationships with loved ones, increased 
energy levels and feelings of optimism. Better sleep quality and diet were also noted. One respondent 
described his negative experience during the application of chemotherapy at home. It was a patient that 
received the therapy through peripheral venous line and developed a local complication with soft tissue 
necrosis. All others reported very high satisfaction and feeling of safety while receiving chemotherapy at 
home. These results suggest an improvement in quality of life and provide strong support for further 
implementation of methods that allow patients to receive chemotherapy at home.
Keywords: elastomeric pump, patient satisfaction survey, chemotherapy, outpatient care
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P3 - ASSESSMENT OF FATIGUE IN CANCER PATIENTS TREATED WITH 
RIBOCICLIB AND ENDOCRINE THERAPY ACCORDING TO PATIENT 
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Petra Lepetić1, Petra Linarić1, Dejana Jezernik2, Kristina Kanceljak2, Ana Tečić Vuger1,  
Mirjana Pavlović1, Ljubica Vazdar1, Robert Šeparović1,3
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Around 70% of metastatic breast cancers have hormone receptor (HR) positive, HER2-negative biol-
ogy and selective cyclin-dependent kinases 4/6 (CDK 4/6) inhibitors, in addition to endocrine therapy (ET), 
are standard of care in the first line, and effective treatment option in subsequent lines of therapy. One of 
the main purposes of treatment in a metastatic setting is maintaining a good quality of life. These agents 
have shown acceptable and easily manageable toxicity profile. It has been described that health care pro-
fessionals underestimate side effects of specific antineoplastic treatment, such as endocrine therapy, com-
pared with patients themselves. Fatigue is indistinct, not well defined, multidimensional symptom which 
is not easily measurable. It is well known that menopause also can cause fatigue, as well as endocrine 
treatment so it’s challenging to determine if this symptom is predominantly caused by menopausal status 
or specific oncological treatment, but it is most likely that the impact of these factors overlap. Nevertheless, 
fatigue is a symptom that negatively impacts patients’ quality of life. This analysis evaluated patient-
reported outcomes (PROs) to assess fatigue and its impact on health-related quality of life in patients with 
HR-positive, HER-2 negative metastatic disease treated at University hospital for tumors. We obtained 
data from 99 patients with HR-positive HER2- negative breast cancer who were treated at the Division of 
Medical Oncology with ribociclib and endocrine therapy, in the period from 08/2018 to 12/2020 and had 
reported fatigue as an adverse event. Patients had to complete at least one four-week cycle of therapy and 
fill in the questionnaires. PRO assessments were evaluable for 87 female patients, median age of 60 years, 
all postmenopausal. Endocrine partners in treatment with ribociclib were aromatase inhibitors in around 
65%, predominantly anastrozole, while in around 35% of patients partner was fulvestrant. During therapy 
with ribociclib, 80% of patients reported fatigue as an adverse effect of this specific antineoplastic treat-
ment. We have shown that fatigue is common in this observed population, and with this analysis from real 
clinical practice, we indicate the requirement for a better understanding of symptoms experienced by 
patients on this precise therapy. Since this symptom is not easy to define, we consider that it is necessary 
to carefully plan further researches to better identify and objectify it. Although not a life-threatening 
adverse event this is challenging symptom for patients, because of its feasible severe distress potential.
Keywords: HR+ breast cancer, ribociclib, CDK 4/6 inhibitors, fatigue
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P4 - ATEZOLIZUMAB IN THE SECOND LINE TREATMENT  
OF METASTATIC UROTHELIAL CANCER THE FIRST EXPERIENCE  
OUTSIDE OF CLINICAL TRIAL
Lazar Popović1,2 Maja Popović1,2 Maša Jović1, Gorana Matovina Brko2
1 Medical Faculty, University of Novi Sad, Novi Sad, Serbia  
2 Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Introduction: Checkpoint inhibitors have dramatically changed the landscape of treatment for 
patients with metastatic urothelial cancer. Since 2016 PD-1 inhibitors (pembrolizumab and nivolumab), as 
well as PD-L1 inhibitors (atezolizumab, durvalumab and avelumab) had been approved for the treatment 
of patients who progressed after the first line platinum based chemotherapy. Before this the only approved 
therapeutic option was vinflunin with median overall survival (OS) of 7 months.
Patients and methods: We present data for 17 metastatic urothelial cancer patients treated with sec-
ond line atezolizumab at Oncology Institute of Vojvodina, Serbia from 2018 to 2021. Progression free sur-
vival (PFS) and OS curves were calculated using Kaplan –Meier method.
Results: Median age was 67. There were four female and 13 male patients. In the first line two patients 
were treated with carboplatin, 15 patients received cisplatin. Seven patients (53,8%) had visceral metasta-
ses, five (29,4%) had bone metastases, 6 (35,3%) had lymph node metastases. Majority of the patients (59%) 
had one metastatic site. Majority of the patients (88%) were in good clinical shape with ECOG performance 
status 0 or 1. Median number of immunotherapy cycles was 4 (1-17). Adverse events were recorded in 
three patients: one patient had hypothyroidism, one patient had neurologic symptoms of undetermined 
cause and one patient had hyperprogressive disease. Median PFS was 3 months (1-26). Median OS was 5 
months (1-26). Best objective response rates are as follows: two patients (12,5%) had partial response, three 
(18,7%) had stable disease while 11 (68,7%) patients had progressive disease.
Conclusion: Patients with metastatic urothelial cancer who progress on the first line platinum based 
chemotherapy have poor prognosis. Our data are in consistence with the results of randomized prospec-
tive phase 3 trial IMVigor 211: median OS was 8,6 months, while PFS was 2,1 months. Patients that were 
in good PS with low tumor burden and no visceral metastases had numerically longer PFS and OS.
Keywords: atezolizumab, metastatic urothelial cancer, second line treatment
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P5 - BODY COMPOSITION OF BREAST CANCER PATIENTS TREATED WITH 
ADJUVANT CHEMOTHERAPY AND ITS INFLUENCE ON QUALITY OF LIFE
Mirjana Pavlović1, Robert Šeparović1,2, Ljubica Vazdar1, Ana Tečić Vuger1, Petra Lepetić1, Petra Linarić1
1Department of Medical Oncology, Division for Medical Oncology, University Hospital for Tumors,  
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2 Juraj Dobrila University of Pula, Pula, Croatia
Body composition has been studied relatively recently as part of oncology trials in different types of 
tumours in the context of the metabolism of different anticancer drugs, the assessment of response to treat-
ment and its toxicity, and consequently the overall prognosis of the disease depending on the proportion of 
each body component. There are numerous studies that clearly define the impact of chemotherapy and its 
side effects on quality of life of breast cancer patients, however there have been few studies that have anal-
ysed the impact of body composition on chemotherapy tolerance as well as on the quality of life of premeno-
pausal patients in the course of cytotoxic treatment. The study was performed on a consecutive sample of 
patients treated with neoadjuvant or adjuvant chemotherapy for early-stage breast cancer at the daily hospi-
tal of the Department of Medical Oncology of University hospital for Tumors in Zagreb between December 
2018. and April 2019. All patients were premenopausal (study allowed inclusion of patients who have had 
their last menstrual cycle within one year before the start of treatment). All patients received four cycles of 
AC chemotherapy (doxorubicin + cyclophosphamide) every three weeks, before or after the surgery. The 
total dose of doxorubicin administered was 240 mg/m2 and cyclophosphamide 2400 mg/m2 for all patients. 
During the each visit patients filled standardized quality od life questionnaires (EORTC QLQ-C30 and QLQ-
B23) and patient’s body composition was estimated using Tanita BC-420MA analyzer. The data were pre-
sented as averages with standard deviations for numeric data, or numbers and percentages for categorical 
data. The testing was performed with Pearson’s correlation coefficient. All analyses were performed in R, 
with significance set at P<0.05. The study included 68 patients with median age of 46,6 years (range 29-55 
years). Analysis of the results of body composition measurements in correlation with QoL showed the impact 
of body composition on certain QoL subdomains during treatment. At the beginning of treatment, the most 
pronounced was the connection between body composition and physical and sexual functioning and hair 
loss. In the second cycle, significant quality-of-life result included financial problems, while in subsequent 
treatment cycles other variables begin to significantly affect subdomaines of quality of life, in particular 
fatigue and diarrhoea. At the beginning of the study, at the first measurement, patients with higher body 
mass and increased visceral fat index have shown worse physical performance than other patients. During 
the entire study, sexual functioning in patients with higher visceral fat index was significantly reduced. In a 
later course of the study, it was shown that body composition significantly influenced the occurrence of 
fatigue during treatment, that is, that patients with a higher percentage of body fat and visceral fat index 
were significantly more tired than patients who had a higher percentage of muscle mass. In conclusion, our 
research showed significant correlation between some components of body composition and QoL subdo-
mains in premenopausal patients with early breast cancer treated with chemotherapy. This kind of informa-
tion can be used in planning interventions for specific subgroup of patients which can bring an improvement 
in the patient’s well-being during chemotherapy, improve patient’s adherence to therapy and thus indirectly 
influence prognosis of the disease. This research has some limitations including unrandomized design, 
which could have led to significant deviation of the results, small sample size and most importantly indi-
vidual characteristics of each patient which may significantly affect the studied parameters.
Keywords:  body composition, bioelectric impedance, breast cancer, adjuvant chemotherapy, quality of life
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P6 - BRAF POSITIVE MALIGNANT MELANOMA: CASE REPORT
Emina Borovac-Gurda1, Benjamin Bećirević2
1Clinic for Oncology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina  
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Background: Melanoma regularly exhibits extremely aggressive biological behavior, and resistance 
to therapy causes 80% mortality from all skin tumors. Pathohistological findings should also include data 
on the presence or absence of ulceration, number of mitoses per mm, Clark level (especially for lesions <1 
mm), edge data. Molecular and genetic understanding of melanoma tumor cells has led to the develop-
ment of targeted therapy as one of the ways to treat this disease. Therefore, the determination and analysis 
of genetic changes in melanoma samples becomes an indispensable part of diagnosis, prognosis and pre-
diction of response to therapy. Mutation of the BRAF gene most commonly occurs at 600 codons.
Case report: The patient is 54 years old. In May 2011, a dermatoscopically suspicious lesion on the 
skin of the left forearm was surgically removed. The histopathological finding was melanoma cutis, Bres-
low 2 mm thick, with stage pT3. According to the recommendation of the multidisciplinary team, re-
excision was performed with a sentinel lymph node biopsy and the final stage of the disease was III a. 
According to the protocol, regular monitoring is indicated. Regular follow-up was performed until 2013, 
after which the patient did not come for check-ups for paramedical reasons. In that period in 2012, another 
skin lesion appeared on the same forearm, was surgically removed and melanoma was diagnosed histo-
logically. Only after 5 years does the patient come for an oncologist examination. Clinical examination 
revealed a 15 mm diameter nodule on the left forearm, immobile without surface changes. After ultra-
sound examination, excision was performed and histologically diagnosed metastatic melanoma of the 
skin and subcutaneous tissue. Due to the resection of R1, a re-excision was performed. Subsequently, an 
assessment was performed based on ultrasound and chest X-ray, as well as a complete laboratory test 
involving LDH. All findings were orderly. According to the protocol, BRAF testing and PET CT scan were 
performed. A mutation in V600E was found on the BRAF gene, and PET CT had no pathological findings. 
According to the guidelines, adj. therapy. iBRAF / MEK. However, at that time the therapy was not funded 
by the Fund. In June 2018, during a regular examination, a protrusion of the right bulb was clinically 
detected. An MRI scan was performed that showed inhomogeneous tumor formation in the retrobulbar 
right muscle. This was consistent with the primary diagnosis that it was most likely a metastasis of mela-
noma. A multidisciplinary team with an ophthalmologist decided to surgically remove the tumor ex tem-
pore by biopsy. Histological diagnosis of ex tempore biopsy was benign muscle tumor, but after examina-
tion of the entire tumor and immunohistochemical analysis, the final diagnosis was metastatic melanoma 
to the retrobulbar muscle. Subsequently, therapy for metastatic BRAF-positive melanoma was initiated. 
All subsequent examinations showed normal findings, including CT and PET CT scans, ultrasound exam-
inations, ophthalmological and dermatological examinations. The patient was without signs of illness and 
without symptoms and adverse events. But in laboratory tests, LDH began to show an increase in value. 
Control CT scanner in January 2019 and CT scanner in April 2019, which were without pathological find-
ings. A reassessment of treatments in May 2019 revealed the following: LDH findings continue to vary 
with values up to 25 percent higher than normal. And the last PET CT showed two small 6 mm diameter 
changes in the right lung lobe without FDG accumulation. In November 2020, the CT finding indicates the 
still present irregularity of pleural thickening in the lower right pulmonary lobe, and a pair of small sub-
pleural thickenings in the lower left pulmonary lobe, which appears on the right in discrete regression 
Lib Oncol. 2021;49(Suppl 2):35–71
44
compared to the previous finding. dg. may correspond to changes in the procedural etiology, although 
given the reference diagnosis, another etiology cannot be ruled out with certainty. CT finding of neurocra-
nium and CT of abdomen and pelvis: still without evident CT signs of pathological changes.
Conclusion: Time from diagnosis of primary disease to metastatic disease more than 7 years. Ther-
apy is indicated for metastatic melanoma BRAF positive. Therapy received after complete surgical removal 
of retrobulbar metastasis. (June 2018). Dabrafenib / Trametinib therapy has been administered for the last 
32 months. Last 32nd cycle issued on 29.03.2021. Reassessment planned with findings: CT of the thorax, 
abdomen and small pelvis, and MRI of the head.
Keywords: malignant melanoma, retrobulbar right muscle metastasis, BRAF mutation.
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Ljubica Vazdar1, Mirjana Pavlović1, Ana Tečić Vuger1, Petra Lepetić1, Petra Linarić1, Robert Šeparović1,2
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According to the results of randomised clinical studies, cardiac toxicity of palbociclib is clinically 
irrelevant compared to other CDK4/6 inhibitor ribociclib. Data from real world studies showed a signifi-
cant difference in incidence of cardiac toxicity (atrial fibrillation, cardiac failure, myocardial infarction) 
between two drugs – 2.2% with palbociclib compared to 7.7% with ribociclib. We conducted retrospective 
analysis of data collected for four advanced breast cancer patients, median age 64 (52-78 years) with his-
tory of cardiovascular diseases and significant heart risk factors (dilatative cardiomyopathy NYHA II/III, 
atrial fibrillation, hypertension, implantation of pacemaker), treated with combination of palbociclib and 
fulvestrant in first line treatment of metastatic hormon sensitive HER2 negative breast cancer. Initial car-
dial status showed no clinical signs of cardial failure, average heart frequency was 60-75/min, systolic 
function of left ventricle was reduced with ejection fraction (LVEF) of 45-53%, QTcF was 415-450 msec. 
Beside perscribed cardiac therapy patients had no comedication which could influence QTcF interval. 
During the treatment period (3-15 months) LVEF was stabile, no changes in the ECG record, in terms of 
emerging repolarisation disorders with changes in QTcF interval, and no clinically significant deteriora-
tion in cardiac function were observed while all patients benefited from therapy in terms of disease con-
trol. Combination therapy of palbociclib and fulvestrant showed no safety concerns in patients with sig-
nificant cardiac comorbidity and increased cardiac risk.
Keywords: palbociclib, cardiotoxicity, breast cancer
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P8 - CASE OF RECCURENT UTERINE ADENOSARCOMA  
WITH SARCOMATOUS OVERGROWTH (ASSO)
Berisa Hasanbegović1, Emir Sokolović1, Benjamin Bećirević2
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Background: Adenosarcomas are rare malignancies of the female genital tract, accounting for approx-
imately 5 % of uterine sarcomas. It is defined as a biphasic tumour composed of both sarcomatous stroma 
and benign epithelium. The majority of patients present with stage I disease, with a 5-year overall survival 
of 60 to 80 %. Standard of care treatment is total hysterectomy with bilateral salpingo-oophorectomy with-
out lymphadenectomy, as the incidence of lymph node metastasis is rare. There is no defined role for 
adjuvant or neoadjuvant chemotherapy or radiation. Although uterine adenosarcomas are typically low- 
grade tumours with a good prognosis, uterine adenosarcoma with sarcomatous overgrowth (ASSO) is a 
rare and aggressive disease and results in a higher rate of death and recurrence.
Case report: A 65-years old patient with previous history of uterine fibroids presented with painful 
pressure in the lower abdomen without signs of vaginal bleeding or discharge. She had a past medical 
history of cervical conisation because of cervical dysplasia 30 years ago. Ultrasound showed enlarged 
uterus and multidisciplinary team recommended radical hysterectomy with bilateral adnexectomy. 
Patient underwent surgical treatment in the November of 2019. Patohistological analysis revealed high 
grade uterine adenosarcoma with sarcomatous overgrowth, pT1bNxMx FIGO IC. The proliferation index 
– Ki67 was over 30%. Postoperative abdominal and pelvic MRI and thoracic CT scan performed in the 
December, 2019 showed no signs of residual or metastatic disease. Adjuvant chemotherapy was initiated 
(6 cycles of mesna, doxorubicin, and ifosfamide – MAI) in the January, 2020. In the April, 2020 patient felt 
a sudden pain in the lower abdomen. Attending gynaecologist performed ultrasound examination which 
revealed anechoic zone with characteristics of liquid collection with a diameter of 29x18 mm located on the 
right side of urinary bladder, in the projection of the right ovary. Based on the ultrasound examination it 
was suspected that described, anechoic zone was abscess, but further diagnostic evaluation was recom-
mended. In the early May of 2020 patient underwent abdominal and pelvic CT scan which revealed oval 
area with a diameter of 45x26 mm located on the right side of the urinary bladder. Based on radiologic 
characteristics described area corresponded to the recurrence of adenosarcoma. In the July of 2020 patient 
underwent surgical resection of suspicious mass. Patohistological analysis confirmed that the resected 
mass represents recurrence of the primary disease. Tumour tissue was dominantly composed of mesenchi-
mal component, without epithelial tissue. Immunohistochemical status of the tumour was SMA and 
h-Caldesmon positive, but desmin negative. In order to define plan of treatment PET/CT was performed 
in August of 2020. It showed solitary lesion, probably residual tumour located along craniodorsal wall of 
bladder with diameter of 15mm. NGS genomic testing of the tumour was performed in the October, 2020. 
Analysis showed that genomic profile of tumour is MS stable, TMB 6 mut/Mb, KIT, PDGFRA, EPHB1, 
JUN, KDR amplification, CDKN2A/B loss, PT53 P278T but without available therapies with proven clini-
cal benefit for this kind of tumour. Based on the results of NGS testing (KIT and PDGFRA amplification) 
possible therapies with clinical benefit in other tumour type were: imatinib, nilotinib, sorafenib, sunitinib. 
After the patient consulted several centres for a second opinion, it was jointly decided to start SBRT of the 
target area in the small pelvis. During the period from November 30 to December 4, 2020, the patient 
received a TD 25Gy/5 fr on the target lesion representing residual tumour. In the January of 2021 reevalu-
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ation was done with MRI and it showed stable disease, stationary size of residual tumour with radiologic 
signs of postiradiational fibrosis.
Conclusion: Uterine adenosarcoma with sarcomatoid overgrowth is rare variant of uterine sarcomas 
with aggressive clinical course. Therapeutic options and benefit of chemotherapy and radiotherapy is still 
unclear. We presented a case of 65 years-old patient with recurrence of the disease during the adjuvant 
chemotherapy. Comprehensive genomic profile could not reveal potential targeted therapy with proven 
clinical benefit for this type of tumour. SBRT was performed to the area of residual tumour which resulted 
with stable disease and stationary size of the residual tumour one month after the therapy. Regular follow-
up of our patient is planned as defined per protocol. Systemic progression of the disease could impose 
challenge for therapeutic decision regarding possible therapies with clinical benefit in other tumour type 
based on KIT and PDGFRA amplification proven in the genomic profile analysis. There is an obvious lack 
of information about rare types of uterine sarcomas. Future similar abstracts and case reports should be 
encouraged.
Keywords: uterine adenosarcoma, sarcomatoid overgrowth, SBRT
Lib Oncol. 2021;49(Suppl 2):35–71
48
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Today, there is still no clear and unambiguous view on the role of androgen receptors (AR) in breast 
cancer, nor in triple-negative breast cancer (TNBC). A series of studies over the years have shown very 
heterogeneous results. Given the lack of a valid biomarker in TNBC, much hope is placed in the prognos-
tic and predictive potential of AR in this aggressive disease. We performed a retrospective cohort study on 
the consecutive sample of 151 early TNBC patients diagnosed and treated at the University Hospital for 
Tumors in 2009-2012. We analyzed AR using immunohistochemistry (IHC), with the cutoff value for posi-
tivity of ≥1%, referring to current ASCO/CAP recommendations on hormone receptor (ER and PR) analy-
sis. The analysis was adjusted for age, comorbidities, menopausal status, histological type of tumor, tumor 
size, number of positive lymph nodes, stage of disease, Ki-67 proliferation index, type of surgery of the 
breast and axilla, and treatment with adjuvant chemotherapy and radiotherapy. Correlations of AR with 
all parameters were calculated, as well as 5 - year disease – free survival (DFS) and overall survival (OS). 
Incidence of AR (≥1%) in patients with early TNBC in our analysis was 31.1%, of which 85% of patients had 
AR≥10% and as many as 60% had AR>50%. AR were found to be statistically significantly positively cor-
related with age and menopausal status, and statistically significantly negatively correlated with tumor 
size, grade and Ki67, as well as disease stage. AR≥1% showed no statistically significant association with 
DFS, median DFS was not reached for both groups of patients, those with AR≥1% as well as those without 
AR, with HR for disease recurrence or death of 1.08. AR were not statistically significantly associated with 
OS, there was no difference in the 5-year OS of patients with AR≥1%, compared with those with AR <1%, 
and median OS was not reached in either group. In this analysis, AR proved to be significantly correlated 
to more indolent, favorable disease characteristics, as expected and seen in many other analyses. However, 
AR did not prove to be an independent factor in the prognosis of patients with early TNBC in this cohort. 
Taking into consideration that there have been some of the larger studies confirming the role of AR as a 
good prognostic factor in this population of patients (although still with many controversies), further 
analyses should consider larger sample size, but also additional molecular markers in TNBC that might be 
in the background of forming the ultimate disease behaviour.
Keywords: triple-negative breast cancer, androgen receptors, biomarker, prognostic biomarker
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P10 - COMPARISON OF PATHOLOGICAL RESPONSE IN HER2 POSITIVE 
BREAST CANCER, MONO VERSUS DUAL ANTI-HER2 BLOCKADE, DATA 
FROM CLINICAL PRACTICE
Jelena Oblaković-Babić, Ivana Božović-Spasojević
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Background: Untreated human epidermal growth factor receptor 2 positive (HER2+) breast cancer 
(BC) is aggressive disease, but its prognosis has been improved by HER2-directing drugs. In neoadjuvant 
setting the first generation of promising targeting HER2 treatment was chemotherapy plus trastuzumab 
and recently the standard first line therapy has become chemo plus dual anti-HER2 blockade (trastu-
zumab and pertuzumab). The pathological complete response (pCR) at time of surgery has been shown to 
predict clinical benefit in patients with early-stage HER2-positive BC, improving disease-free survival, 
event-free survival and overall survival. Across the studies the definition of pCR varies. The most common 
used definitions are: 1) eradication of in-situ cancer and invasive cancer in the breast and axillary nodes 
(ypT0 ypN0) or 2) eradication of only invasive cancer in the breast and axillary nodes (ypT0/is ypN0) or 3) 
eradication of only invasive cancer in the breast (ypT0/is).
Methods: In this retrospective study 178 consecutive patients with invasive HER2+BC were diag-
nosed in clinical stage IA – IIIC and they received neoadjuvant therapy (antracyclines plus taxanes with 
mono vs dual anti-HER2 blockade) in period from 2010 to 2020 at the Institute for Oncology and Radiology 
of Serbia in Daily chemotherapy hospital. The primary end point was to compare pCR in two group of 
patients, mono versus (vs) dual anti-HER2 therapy. We strongly defined pCR as absence of in-situ cancer 
and invasive cancer in both the breast and the axillary lymph nodes. The Second aims of the study were to 
compare the pCR rates in different subpopulation based on age, initial clinical stage, hormone receptor 
(HR) status and type of second line chemotherapy paclitaxel vs docetaxel.
Results: At this point we analyzed patients with unilateral BC who received anthracycline-taxane–
based chemo plus trastuzumab (N=84) or trastuzumab and pertuzumab (N=94). The median age in our 
cohort was 52.5 years (range 26-79). The majority of women had clinical stage IIIA 43.8%, followed by IIIB 
(27.0%), IIA (12.9%), IIB (11.8%), IIIC (3.9%) and only one patient had stage IA (0.6%). The most frequent 
hystomorphological tumor type were ductal IC 54.5%, undefined IC 32.0% and lobular IC 6.7%. The histo-
logical tumor grade 2 was the most common 77%, with the missing data for 16.8% of patients. The overall 
observed pCR rate was 42.7%. We found improved pCR in dual versus mono anti-HER2 therapy (49.5% vs 
34.5%, p<0.05). The patient with HR negative status had higher pCR rate 49.3% (34/69) comparing with 
positive HR status 38.5% (42/109) without statistical significance, p=0.17. Although pCR rates were numer-
ically higher in women older than 50 years versus younger women (47.0% vs 37.2, p = 0.22) and in group 
with the initial clinical stages IA-IIB versus more advanced stages IIIA-IIIC (51.1% vs 39.8%, p=0.22), dif-
ferences were not statistically significant. The choice of taxane drug (paclitaxel vs docetaxel) did not influ-
ence pCR (43.0% vs 38.8%, p=0.73).
Conclusion: In accordance with previous neoadjuvant studies in patients with HER2-positive BC 
dual anti- HER2 blockade increases pCR compared with mono anti-HER2 treatment. The more frequent 
pCR was achieved in subgroup with HR negative tumor than with HR positive tumor.
Keywords:  HER2 positive breast cancer, neoadjuvant therapy, anti-HER2 therapy, pathological 
 complete response
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P11 - COVID-19 VACCINATION IN PATIENTS WITH CANCER  
– SINGLE INSTITUTIONAL EXPRERIANCE
Ognjen Djurmez, Marina Čalamać, Marija Dimitrijević, Jelena Oblaković-Babić, Ivana Minić,  
Zoran Tomašević, Ivana Božović-Spasojević
Daily Chemotherapy Hospital, Medical Oncology Clinic, Institute for Oncology and Radiology of Serbia,  
Belgade, Serbia
Introduction: COVID-19 infection is the biggest global health treats worldwide, which has now 
infected over 150 million people with death range over 3 million. Cancer patients are usually more sensi-
tive to infective diseases than people in overall population especially those receiving highly myelosup-
pressive chemotherapies. Coronavirus pneumonia led to 24% mortality with frequently extended viral 
shedding in cancer patients compared to 3% in noncancer patients. Because of its rapid spread in human 
population, the most effective management strategies are protective measures for preventing further 
transmission of the virus. Therefore, vaccines against SARS-CoV-2 are the promising solution to minimize 
the spreading of the virus. There are still limitations to be considered, including the efficacy of COVID 
vaccines for immunocompromised individuals. Patients with an active cancer should be considered for 
priority access to COVID-19 vaccination. The aim of our study was to examine number of patients vacci-
nated against SARS-CoV-2 virus, type of vaccines they received and side effects of the vaccination.
Methods: Between February and April 2021. we collected data from 87 oncology patients that have 
received vaccine against SARS-CoV-2 virus. All of the patients, at the time of the vaccination, were actively 
treated at the Daily Chemotherapy hospital at IORS, Institute for Oncology and Radiology of Serbia. 
Demographic data, oncology diagnosis, current treatment modality and co-morbidities were collected 
from patients’ electronic records. Information’s of the vaccination such as date of the first and second dose 
of received vaccine, type of the received vaccine and side effects were collected by questionnaire which 
was previously approved by the Ethics Committee of the IORS.
Results: Out of 87 patients, 67 (77%) are female, and 20 (23%) are male. Patients’ mean age at the time 
of the first dose of vaccine received was 62.2 ± 13.4 years. The youngest patient was 39.8 years old, and the 
oldest one was 83.9 years old at the time of the vaccination. Out of 87 patients, 81 of them received both 
doses of the vaccine. 6 patients are still waiting to receive the second dose of the vaccine. 33 patients 
(37.9%) didn’t have any co-morbidities. 28 of them (32.2%) had one and 26 (29.9%) had 2 or more co-mor-
bidities requiring active therapy. In our group, 39 patients (44.8%) had non-metastatic disease and 48 
(55.2%) had metastatic disease, out of whom 29 patients have one organ affected with metastasis and 19 
have two or more affected sites. At the time of the vaccination, 28 patients (32.2%) was receiving cytotoxic 
chemotherapy. Out of 87 vaccinated patients, only 5 of them (5.7%) had previously COVID-19 infection. 
One patient had COVID-19 infection 5 days after receiving second dose of vaccine. Patient had mild symp-
toms with normal chest X-ray findings. She has fully recovered and continue her oncology treatment. 63 
patients (72.4%) received vaccine made by Sinopharm company, followed by Pfizer-BioNtech vaccine (11 
patients, 12.6%), Sputnik V (8 patients, 9.2%) and Oxford/AstraZeneca vaccine (5 patients, 5.7%). Out of 87 
patients, 66 of them (75.9%) didn’t have any side effects after receiving the vaccine. Only 11 patients (12.6%) 
had 2 or more different symptoms. The most common side effect was pain at the injection site of the vac-
cine and it was present in 10 patients (11.5%). 9 patients (10.3%) reported chills and shivering. Fever was 
present in 8 patients (9.2%). Only two patients had allergic-like reactions that was present with skin rush. 
None of the patients had severe allergic reactions.
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Conclusion(s): In our study 87 patients with solid tumors and active oncology treatment had been 
vaccinated against SARS-CoV-2 virus without severe side effects. Although our study has a small number 
of patients vaccination against SARS-CoV-2 is safe. We will follow further our patients for possible COVID-
19 infection. Our study support current guidelines which promote vaccination in oncology patients as 
priority.
Keywords: oncology patients, SARS-CoV-2 virus, vaccination
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P12 - CURRENT STRATEGIES TO IMPROVE RESECTABILITY  
OF COLORECTAL LIVER METASTASES
Hrvoje Silovski, Ivan Romić, Ante Gojević, Tomislav Baotić, Igor Petrović, Ognjan Deban,  
Goran Pavlek, Ivan Šeparović, Jurica Žedelj, Iva Martina Strajher, Boško Romić
Department for Surgery, University Hospital Centre Zagreb, Zagreb, Croatia
Around 25% of colorectal cancers manifest with liver metastases (CRLM) during the course of the 
illness, and surgical resection offers the only hope of cure and long-term survival. However, at the time of 
diagnosis, most patients have irresectable tumors due to inadequate healthy liver parenchyma that could 
be spared with standard liver resections. FLR of >30% is required for safe resection of healthy liver and 
>40% for the cirrhotic liver. Neoadjuvant chemotherapy can reduce the size and number of CRLMs, con-
verting 10-20% of patients into resectable ones, but in case of failure, the prognosis is poor. Regenerative 
liver surgery was developed in order to prevent post hepatectomy failure by promoting liver hypertrophy 
prior to a definitive surgical procedure. Different approaches are available, including portal vein emboli-
zation (PVE), 2-stage hepatectomy and novel method: Associating liver partition and portal vein ligation for 
staged hepatectomy (ALPPS). In the first stage of ALPPS, the liver is transected between the healthy and 
diseased lobe along with the ligation of the portal vein that supplies the part to be removed. After 1-2 
weeks and adequate FLR hypertrophy, a second stage which includes the removal of the diseased liver 
lobe, is performed. The main advantage of ALPPS over other methods is faster and more intensive liver 
hypertrophy (mean FLR increase is 75%). Improvement in operative technique and postoperative care 
allowed the performance of ALPPS with acceptable mortality (7%) and morbidity rate (25%). In addition, 
these patients achieved an appealing long-term oncologic outcome (1-year disease free rate of 70%). The 
management of CRLM should always be based on a multidisciplinary paradigm with emphasis on tumor 
biology and personalized approach. The role of liver transplantation, hepatic vein embolization, and stan-
dard loco-regional therapies is yet to be addressed.
Keywords: liver, colorectal, cancer, regeneration
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P13 - DUAL BLOCKADE WITH PERTUZUMAB/TRASTUZUMAB VERSUS 
TRASTUZUMAB IN NEOADJUVANT TREATMENT OF HER2 POSITIVE 
BREAST CANCER
Maja Popović1,2, Gorana Matovina Brko2, Maša Jović1, Jasna Pešić1, Jasna Trifunović1,2, Lazar Popović1,2
1Medical Faculty, University of Novi Sad, Novi Sad, Serbia  
2Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
We present data of HER2 positive early breast cancer patients treated with neoadjuvant chemother-
apy at Oncology Institute of Vojvodina from 2015 until 2020. The first anti HER2 standard of treatment 
were neoadjuvant antracycilnes followed by trastuzumab and taxanes (AC/HT) until October 2018, when 
dual HER2 blockade (AC/PHT) became available in Serbia.
Results: We identified 108 patients treated with neoadjuvant chemotherapy in this period. Total 
pathologic complete response (pCR) was defined as the absence of residual invasive and in situ cancer 
after neoadjuvant treatment. Median age was 54 (27-79). Among HER2 positive patients there were 41 
(37.9%) hormone receptor negative patients (ER value 0), 21 (19,4%) intermediate hormone receptor posi-
tive patients (ER value 1 to 6), and 46 (42,5%) hormone receptor positive patients (ER value 7 and 8). Thir-
tyeight (38) patients were treated with AC/HT regimen, 94% of them were clinicaly node positive, 27,5% 
had tumor smaller than 3cm. Seventy (70) patients were treated with AC/PHT, 60% of them were clinicaly 
node positive, 52,2% had tumor smaller than 3cm. Total pCR rate in AC/HT group was 17,9%, and 50,7% 
in AC/PHT group p=0,0008. Breast pCR rate in AC/HT group was 41%, and 52,2% in AC/PHT group. In the 
hormone receptor negative group total pCR rates were: 35,7% for AC/HT regimen, and 65,2% for AC/PHT. 
In the intermediate hormone receptor positive group tpCR rates were 25% for AC/HT regimen and 53,3% 
for AC/PHT regimen. In the hormone receptor positive group tpCR rates were: 6,6% for AC/HT, and 33,3% 
for AC/PHT p=0.049. In the hormone receptor negative group pCR rates in breast were: 50% for AC/HT 
regimen, and 65,2% for AC/PHT. In the intermediate hormone receptor positive group pCR rates in breast 
were 42,8% for AC/HT regimen and 53,3% for AC/PHT regimen. In the hormone receptor positive group 
pCR rates in breast were: 33,3 % for AC/HT, and 40% for AC/PHT.
Conclusion: These results are in consistence with large prospective phase 3 clinical trials that led to 
approval of trastuzumab and later pertuzumab in the neoadjuvant treatment of HER2 postive breast can-
cer, as well as numerous real-world data published in the past years. Higher precent of node positive and 
large tumors in AC/HT group is in accordance with previously used criteria for neoadjuvant chemother-
apy, while introduction of dual blocade led to a new standard of treatment that completely changed the 
mindset of oncology professionals.
Keywords:  HER2+ breast cancer, neoadjuvant therapy, dual blockade, total pathological complete 
response
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P14 - EFFICACY OF BIWEEKLY CETUXIMAB-IRINOTECAN COMBINATION 
IN THIRD LINE TREATMENT OF PATIENTS WITH METASTATIC 
COLORECTAL CANCER
Vladimir Nikolić, Nemanja Stanić, Marija Ristić, Neda Nikolić, Jelena Spasić,  
Feđa Đorđević, Davorin Radosavljević
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Introduction: Cetuximab is an IgG1 chimeric monoclonal antibody directed against the extracellular 
domain of epidermal growth factor receptor (EGFR). It has antitumor activity in patients without muta-
tions of the RAS gene. Its combination with irinotecan is widely used in heavily pretreated patients pro-
gressing on at least two lines of systemic chemotherapy. Weekly Cetuximab administration is the standard 
regimen in patients with metastatic colorectal cancer (mCRC), but bi-weekly regimen is more convenient 
for the patients. Cetuximab has been reimbursed by the Serbian Health Insurance Fund from 2009.
Method: This is a retrospective study of Cetuximab-Irinotecan combination every two weeks in 
patients with KRAS wild type gen who previously progressed on oxaliplatin and irinotecan based regi-
mens. Genomic DNA was extracted from formalin-fixed paraffin embedded tumor tissue samples and 
real-time PCR was used for RAS mutation detection. Cetuximab was used in dose of 500mg/m2 and Irino-
tecan in dose of 180mg/m2. Response was evaluated every 2 months. Treatment was applied until disease 
progression or unacceptable toxicity.
Results: 204 patients were treated with Cetuximab-Irinotecan combination, after disease progression 
on at least two lines of systemic treatment. 132 patients were male (65%) and 72 female (35%), with median 
age at diagnosis 61 years (range 24 to 81). Median number of Cetuximab was 10 (range 1-50). Best therapy 
response was a partial response in 40 patients (19%), stable disease in 113 patients (56%), and progression 
in 51 patients (25%). Median progression-free survival (PFS) was 6.67 months (CI 95% 5.95-7.38). Median 
overall survival (OS) was 10.4 months. There was no statistically significant difference in PFS regarding 
gender, age, sidedness of primary tumor (left vs right), and localization of metastatic sites.
Conclusion: In our experience, Cetuximab given every other week is an optimal treatment choice in 
chemotherapy pretreated patients with wild type RAS gene. It showed a good response rate as well as 
progression free and overall survival.
Keywords: biweekly cetuximab, third line treatment, metastatic colorectal cancer
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P15 - ENDOCRINE VERSUS CHEMOTHERAPY IN METASTATIC  
HR+/HER2- BREAST CANCER
Gorana Matovina Brko1, Maja Popović1,2, Jasna Trifunović1,2, Jasna Pešić1,, Lazar Popović1,2
1Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia  
2Medical Faculty, University of Novi Sad, Novi Sad, Serbia
Background: Just a few years ago chemotherapy or endocrine therapy were the only possible treat-
ment options of HER2 negative (HER2-), endocrine dependent (HR+) metastatic breast cancer. Guidelines 
were favoring endocrine therapy over chemotherapy, and oncology practitioners were following guide-
lines to a greater or lesser extent.
Patients and Methods: We have conducted a retrospective observational study in order to investigate 
the first line treatment choices for 425 metastatic HER2-/HR+ breast cancer patients diagnosed and treated 
from 2014 until 2018 at Oncology Institute of Vojvodina, Serbia. We have assessed the potential parameters 
that may influenced the treatment choice. Progression free survival (PFS) curves were calculated using 
Kaplan –Meier method.
Results: Patients’ median age was 63 (28-85), majority were postmenopausal (86,5%), 114/425 (27%) 
patients had de novo metastatic disease. Almost half of the patients were treated with chemotherapy in the 
first line 218/425 (48,6%). These patients were significantly younger, had less comorbidities, had more 
metastatic sites, had visceral disease and were less likely to have bone only metastases in comparison to 
patients treated with endocrine therapy in the first line. Primary endocrine resistance (relapse during the 
first 24 months of adjuvant hormonal treatment) did not influence the first line choice of treatment (p=0,65). 
Median PFS for initial chemotherapy was 6 months versus 12 months for initial endocrine therapy p<0.0001 
HR 0.57 (0.45-0.73). First line chemotherapy was not associated with better outcome in comparison to 
endocrine therapy even in patients with primary endocrine resistance: mPFS was 6 vs 12 months: p<0.0032 
HR 0.47 (0.26-0.85). First line choices have been evolving through the years: in 2014 and 2015 35% of the 
patients were treated with endocrine therapy in comparison to 55% in 2016 and 2017.
Conclusion: Although guidelines have recommended endocrine therapy in the first line treatment of 
metastatic HER2-/HR+ breast cancer, our data are in consistency with other real-world data, suggesting 
that high percentage of patients have been treated with first line chemotherapy. This strategy is not associ-
ated with better outcomes even in patients with primary endocrine resistance.
Keywords: breast cancer, metastatic, chemotherapy, endocrine therapy, progression-free survival
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P16 - GASTRIC METASTASIS 15 YEARS AFTER RADICAL MASTECTOMY 
FOR PRIMARY BREAST CANCER: CASE REPORT
Emir Sokolović, Mujo Kadrić
Clinic of Oncology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Background: Breast cancer is one of the leading cause of cancer-associated mortality worldwide, and 
its incidence is continuously increasing. The most common metastatic sites of breast cancer are the bone, 
brain, liver and lungs, but patterns of metastasis are affected by the breast cancer subtype. Gastrointestinal 
metastases from breast cancer are rare. The incidence of gastrointestinal metastases from breast cancer in 
long-term series and autopsies ranges between 2% and 18%. However, the rate of gastrointestinal (GI) 
metastasis from breast cancer is considered to be <1% in the clinical setting.
Case report: A 63-years old female patient underwent mammography and FNA biopsy after she dis-
covered a suspicious lump in her left breast during self-examination. After patohistological confirmation 
of malignant disease, radical mastectomy was performed in the May of 2006. Pathologic analysis showed 
G1 tubular invasive breast cancer pT4 N0 (0/25) M0. Immunohistochemistry analysis revealed that tumour 
is ER-positive, PR-positive, Her2-negative. Adjuvant chemotherapy was initiated (6 cycles of FEC proto-
cole: 5-FU, Farmorubicin, Endoxan) followed by hormonal therapy based on the immunohistochemical 
status of the tumour. Because of febrile neutropenia after 5th cycle, chemotherapy was stopped and the 
patient underwent thoracic wall irradiation with TD 50 Gy. In the November of 2006 hormonal therapy – 
tamoxifen was initiated. In the November of 2007 transvaginal ultrasound revealed endometrial hyperpla-
sia, tamoxifen was discontinued and letrozole was initiated as an adequate substitution. Adjuvant hor-
monal therapy was discontinued in the November of 2017. Regular follow up was suggested as defined 
per protocol. In the March, 2021 patient presented with haematemesis, anaemia and fatigue. She under-
went proximal gastrointestinal endoscopy which revealed a tumour arising from the gastric wall. Pato-
histological analysis and imunohistochemical profile suggested Er-negative, Pr-negative, Her2-positive 
metastatic breast cancer. Abdominal CT scan showed infiltration of stomach with pathologically enlarged 
lymph nodes next to the lesser curve of the anterior gastric wall. Liver was enlarged with multiple focal 
areas (secondary deposits). CT also revealed multiple osteolytic lesions of lumbar spine. Multidisciplinary 
team decided to initiate weekly Paclitaxel for 12 weeks with dual Her2 blockade: trastuzumab + pertu-
zumab. Patient is currently undergoing the therapy. After 5 cycles of Paclitaxel and 2 cycles of trastuzumab 
+ pertuzumab she is feeling better with significant clinical improvement.
Conclusion: We report a case of a female patient at the age of 78 presented with an acute episode of 
haematemesis with previous anaemia and fatigue. Diagnostic evaluation revealed gastric, liver and bone 
metastases 15 years after radical mastectomy and more than 3 years after ending the adjuvant hormonal 
therapy. Although primary tumour was luminal A, gastric metastasis underwent molecular subtype 
change. Systemic treatment was initiated based on immunohistochemical profile of the gastric metastasis. 
Gastrointestinal metastases from breast cancer are considered rare in the clinical setting. However, 
patients with anaemia and/or other gastrointestinal symptoms occuring many years after diagnosis of 
primary breast cancer should be properly evaluated with gastrointestinal endoscopy. Molecular subtype 
change in metastatic tumours should be considered.
Keywords: breast cancer, gastric metastasis, molecular subtype, subtype change
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P17 - HYPERPROGRESSIVE DISEASE IN PATIENT WITH METASTATIC 
UROTHELIAL CARCINOMA TREATED WITH ATEZOLIZUMAB – CASE 
REPORT
Maja Popović1,2, Gorana Matovina Brko2, Maša Jović1, Lazar Popović1,2
1Medical Faculty, University of Novi Sad, Novi Sad, Serbia  
2Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Introduction: Until recently, the only approved therapeutic option for second line treatment of meta-
static urothelial cancer was vinflunin with median overall survival (OS) of 7 months. Since 2016 PD-1 
inhibitors (pembrolizumab and nivolumab), as well as PD-L1 inhibitors (atezolizumab, durvalumab and 
avelumab) had been approved for the treatment of patients who progressed after the first line platinum-
based chemotherapy.
Case report: Female patient, 71 years old, with history of arterial hypertension, was diagnosed with 
grade 3 transitiocellular carcinoma of the left kidney in december 2019. She was initially treated with left 
nephroureterectomy and partial cistectomy in december 2019, pT2NxMx. Initial CT scans after surgery 
showed dissemnation ot the disease in the lungs: solitary node 29x25mm localized in S9/10 right lung. She 
was treated with 3 cycles of gemcitabine/cisplatin protocol. CT scans showed partial response in the lungs: 
solitary node reduced in size 16x20mm. She was treated with 3 more cycles of gemcitabine/cisplatin pro-
tocol until August 2020. PET CT revealed solitary node in the lungs 17x21mm SUVmax 9,7. She received 
no further treatment. Follow up CT scans in January 2021 showed progressive disease: enlargement of 
solitary metastasis in the right lung 41x30mm and mediastinal lymphadenomegaly. Since the progression 
was confirmed five months after first line platinum-based chemotherapy, patient began treatment with 
atezolizumab in the second line. Six days after the first cycle of treatment she presented with weakness in 
her lower limbs, elevation of LHD and alkaline phosphatase 2xULN. Two weeks later she was admitted to 
the hospital due to paraparesis. MRI of spine was performed and showed massive progression of disease 
in all spinal vertebra with fracture of VTh10 and ekstraosseal propagation of neoplastic process and spinal 
stenosis. The immunotherapy was stopped, and patient was referred to radiation oncologist for palliative 
radiotherapy. Hyperprogressive disease is defined as tumor growth rate at least twice as high after immu-
notherapy in comparison to beginning of treatment. It is also defined as double increase of the sum of 
target lesions in comparison to the baseline values, and at least two new lesions. It is described in 4-29% 
patients treated with immunotherapy. It is more common in patients older than 65, previously treated 
with radiotherapy and certain gene alterations.
Keywords: hyperprogression, immunotherapy, metastatic urothelial cancer
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P18 – KIDNEY CANCER: HOW COULD WE INTERPRET RADIOLOGIC 
RESPONSE TO IMMUNOTHERAPY?
Ana Koši Kunac, Milena Gnjidić, Borislav Belev
Department of Medical Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Introduction: Immunotherapy represents a significant progress in treatment of malignant disease. 
Considering the specific activity of immunotherapy, applying standard RECIST criteria could lead to dis-
crepancies in radiologic and true stage of tumor disease, resulting in early and potentially unjustified 
therapy discontinuation. In order to circumvent these pitfalls, iRECIST criteria were developed. Their 
specificity comparing previous criteria, is that increase in tumor size at the first control is not unambigu-
ously defined as progressive disease, but further radiologic evaluation is required, resulting in better uti-
lization of immunotherapy potential.
Case report: A 66- year old patient had undergone left sided nephrectomy in year 2000, with patohis-
tologic diagnosis of clear cell carcinoma. In 2015, lung and pancreas metastases were verified, and treat-
ment with sunitinib was started, with discontinuation in 2016 due to nephrotic syndrome. During 2017, he 
underwent stereotactic radiotherapy of lung and pancreas metastases. In April, 2018 immunotherapy with 
nivolumab was started. After 5 cycles, CT reevaluation verified increase in size of lung and mediastinal 
lymph node metastases with slight regression in the size of pancreatic lesion, compared to radiomorpho-
logic status 3 months before immunotherapy inception. In a 2 month interval without therapy, radiologic 
reevaluation showed a stationary constellation regarding lung metastases, with regressive dinamics of 
pancreatic lesion, so immunotherapy with nivolumab was continued. Subsequent CT reevaluation showed 
further metastases regression, and the patient remained in excellent clinical condition. Altogether, till 
April, 2021, the patient is 3 years on nivolumab immunotherapy, radiomorphologically and clinically with 
stable disease.
Conclusion: Considering the specific tumor morphological changes during immunotherapy, modi-
fied radiologic criteria of therapy response evaluation were developed. As presented in this case report, 
radiomorphologic tumor progression does not necessarily implement overall therapy failure. Although 
missing conclusive reccomendations regarding immunotherapy continuation, evidence exist that with 
favourable clinical status it is reasonable to wait even for several months for radiomorphologic tumor size 
regression.
Keywords: kidney cancer, immunotherapy, iRECIST
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P19 - NEOADJUVANT TREATMENT FOR HER2 POSITIVE EARLY BREAST 
CANCER – DIFFERENCES BETWEEN TRASTUZUMAB MONOTHERAPY AND 
DUAL ANTI-HER2 BLOCKADE IN OUR CLINICAL PRACTICE
Petra Linarić1, Ana Tečić Vuger1, Ljubica Vazdar1, Mirjana Pavlović1, Petra Lepetić1, Robert Šeparović1,2
1Department of Medical Oncology, Division for Medical Oncology, University Hospital for Tumors,  
Sestre milosrdnice University Hospital Center, Zagreb, Croatia  
2Juraj Dobrila University of Pula, Pula, Croatia
Neoadjuvant systemic therapy is standard treatment option for the most of HER2 positive early breast 
cancer patients. Studies confirm that patients with pathological complete response (pCR) to neoadjuvant 
therapy have better disease free survival (DFS) and overall survival. It is generally used to downstage the 
tumor which leads to higher rates of breast-conserving surgery rather than mastectomy. The response to 
neoadjuvant treatment informs us of the efficacy of the used therapeutic regimen and, therefore, helps us 
to choose an appropriate treatment strategy. First significant results have been shown in NeoALTTO 
study, which enrolled women with HER2-positive early breast cancer treated with lapatinib and trastu-
zumab and confirmed that patients who achieve pathological complete response after neoadjuvant anti-
HER2 therapy have longer event-free and overall survival. Hence, studies with pertuzumab, such as Neo-
Sphere trial, show improved efficacy when combined with the established HER2-directed antibody trastu-
zumab in breast cancer therapy. According to NeoSphere trial, patients given pertuzumab and trastuzumab 
plus docetaxel had a significantly improved pathological complete response rate compared with those 
given trastuzumab plus docetaxel, with favourable safety profile. At University hospital for Tumors, 
Zagreb, neoadjuvant systemic treatment was officially introduced in May 2015. and during that time, over 
400 patients were treated. Our pilot trial analyzed consecutive sample of first 50 HER2 positive patients 
treated in our Clinic. We’ve analyzed patients characteristics, and compared two cohorts, one treated with 
anti-HER2 monotherapy (trastuzumab) versus the one treated with dual anti-HER2 therapy (trastuzumab 
+ pertuzumab), from the moment dual anti-HER2 therapy became available. In patient cohort who received 
only trastuzumab together with chemotherapy, we enrolled 25 patients, consecutively. This cohort 
included 13 patients with hormone dependent tumors, and 12 patients who had non-luminal tumors. One 
patient in this cohort had multifocal disease, with both luminal biology tumors. Second cohort of patients 
which was treated with dual anti-HER2 therapy (pertuzumab+trastuzumab) plus chemotherapy, included 
13 patients with luminal disease, 11 patients with non-luminal disease, and again, one of the patients had 
two primary tumors, both luminal type. In the cohort treated only with trastuzumab, 8 patients achieved 
pCR (complete pathological response), 3 patients achieved RCB (residual cancer burden) class I response, 
5 of them RCB class II response, and two patients RCB class III response. For 6 patients residual cancer 
burden was not calculated. In the cohort treated with dual anti-HER2 therapy, 10 patients had pCR, 2 
patients had RCB class I response, 8 patients had RCB class II response, 3 had RCB class III response, and 
for 2 patients RCB class was not calculated. In conclusion, there were more patients who achieved com-
plete pathological response in cohort treated with both trastuzumab and pertuzumab. Among the patients 
who achieved pCR with trastuzumab monotherapy, 3 patients had luminal disease, and 4 patients had 
non-luminal tumor. For comparison, in cohort treated with dual anti-HER2 therapy, 4 of patients who had 
complete response to neoadjuvant treatment had luminal and 6 had non-luminal disease. Most of the 
patients in both cohorts who had RCB class II or RCB class III response to treatment had luminal cancers. 
Statistically significant results were not obtained, likely due to the small number of patients included in 
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this preliminary study. However our data clearly showed a trend of improved response to treatment and 
higher pCR in patients treated with both trastuzumab and pertuzumab in contrast to trastuzumab mono-
therapy, as well as tendency for better response rate to neoadjuvant chemotherapy in patients with HER2 
positive non-luminal subtypes, which is consistent with results showed in relevant studies.
Keywords: neoadjuvant treatment, early breast cancer, HER 2 positive
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P20 - PATHOLOGICAL COMPLETE RESPONSE FOLLOWING NEOADJUVANT 
THERAPY FOR GASTRIC CARCINOMA
Emina Borovac-Gurda, Emina Bičakčić Filipović
Department of Oncology, Clinical Center University of Sarajevo, Sarajavo, Bosnia and Herzegovina
Background: Gastric cancer is the fifth most common malignancy and the third most common cause 
of cancer-related deaths worldwide. The incidence has declined over the last decades, but still, there is a 
significant number of new cases per year. A high mortality rate could be contributed to the fact that gastric 
malignancies have a tendency to present in advanced stages, with patients that are usually asymptomatic. 
Surgical resection still remains the only curative treatment for gastric cancer. Even after potentially cura-
tive surgery, overall survival at 5 years for patients with gastric adenocarcinoma remains as low as 20%–
30%. Survival rates in gastric cancer have improved since the implementation of a combined approach of 
surgery and perioperative chemotherapy versus a surgery up-front approach. Neoadjuvant therapy has 
shown various benefits including an improved tolerance of chemotherapy regimen, overall survival and 
disease-free survival, increased probability of achieving negative margins, as well as tumor downstaging. 
These advantages demonstrated in the MAGIC and FLOT4 trials caused a paradigm shift favoring neoad-
juvant chemotherapy followed by surgery and then additional adjuvant chemotherapy as the standard of 
care for patients with locally advanced gastric cancer. MAGIC trial is the first landmark trial, which 
showed overall survival (OS) improvement with perioperative chemotherapy (3 cycles of ECF/ECX) in 
resectable gastric, GEJ junction, and lower esophageal adenocarcinoma. The experimental arm showed 
significant improvement in 5 year OS as compared to surgery alone. The FLOT trials compared two differ-
ent perioperative chemotherapy regimens (FLOT vs ECF/ECX) and findings have shown that overall sur-
vival was increased in the FLOT group compared with the ECF/ECX group for locally advanced, resect-
able gastric carcinoma. The estimated 5-year OS was increased in FLOT group than in ECF/ECX group, as 
well as median OS. Thus, this standard of therapy has not only shown to downstage locally advanced 
tumors but can potentially result in pathological complete response (pCR), although it is rare ranging from 
3 to 15%.
Case report: A 61-year old female patient has presented to the primary care physician complaining of 
abdomen pain and heartburn. Abdominal ultrasound had shown gastric mucosal edema and with prior 
history of heartburns, the patient underwent gastrointestinal endoscopy which revealed a defect in the 
mucosa. The pathohistological analysis identified a grade 3 invasive adenocarcinoma. Abdominal MR 
scan showed a significant infiltration of the stomach with pathologically enlarged lymph nodes without 
signs of pancreatic infiltration or other secondary deposits. A multidisciplinary team (MDT) decided on 
initiating a neoadjuvant chemotherapy prior to doing surgery in the duration of 4 cycles following FLOT 
protocol.
In March 2021, an abdominal CT scan showed infiltrative gastric wall thickening of the greater curva-
ture of the stomach with signs of perigastric fat infiltration. Post-neoadjuvant chemotherapy gastrointesti-
nal endoscopy showed a cobblestone-like appearance of gastric mucosa in place of ulcerative infiltration 
initially described. MDT decided to proceed with surgical treatment. Thus, in late March 2021. The patient 
underwent gastrectomy, omentectomy and lymphadenectomy. Pathohistological analysis confirmed the 
initial diagnosis. A total of 12 lymph nodes were extirpated and had shown only signs of inflammation, 
but no signs of neoplasia. The patient is currently undergoing adjuvant chemotherapy, with no signs of 
recurrence of the primary disease.
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Conclusion: We report a case of a 61-year old female patient presenting with abdominal pain and 
heartburn. Diagnostic evaluation revealed grade 3 gastric adenocarcinoma with signs of local advance-
ment. The patient underwent perioperative chemotherapy according to the FLOT4 trial, afterward follow-
ing successful surgical treatment, with currently ongoing adjuvant chemotherapy. Gastric adenocarci-
noma prognosis remains poor despite recent advances in therapies. The multimodal approach represents 
the standard of care for the treatment of resectable oesophageal and gastric cancer patients today. Various 
trials showed an improvement in overall survival by using a perioperative treatment in comparison to 
surgery alone. A combined approach of surgery and perioperative chemotherapy versus a surgery up-
front approach should be implemented as a staple standard of care for patients with localized or locally 
advanced gastric carcinoma. This is giving a greater chance for a longer OS or even pCR.
Keywords: gastric carcinoma, complete response, neoadjuvant, chemotherapy
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P21 - PATHOLOGICAL COMPLETE RESPONSE RATES WITH DUAL HER2 
BLOCKADE ADDED TO NEOADJUVANT CHEMOTHERAPY IN BREAST 
CANCER: A SINGLE-CENTER EXPERIENCE
Simonida Bobic, Lidija Pavlović, Andjela Karaferić, Marijana Milović-Kovačević, Ljiljana Stamatović
Instute for Oncology and Radiology of Serbia, Belgrade, Serbia
Background: In human epidermal growth factor receptor 2 (HER2)-positive early and locally 
advanced breast cancer (BC) neoadjuvant treatment with a combination of sequential chemotherapy and 
HER2-targeted therapy is currently the standard of care. Studies have shown that patients who achieve 
pathological complete response (pCR) after neoadjuvant treatment have a better long-term outcome.
Objective: The aim of this study is to identify pCR rates in patients with early and locally advanced 
HER2-positive BC receiving neoadjuvant chemotherapy with trastuzumab plus pertuzumab.
Methods: A retrospective single-center review was conducted among HER2-positive early and locally 
advanced BC patients (stage II and III) who received neoadjuvant therapy for two years period (2019/2020). 
All the patients received 4 cycles of anthracycline-containing therapy followed by a taxane (4 cycles of 
docetaxel or 12 weekly application of paclitaxel) in combination with of trastuzumab and pertuzumab. 
Complete pathological response was defined as the absence of residual invasive cancer both in the breast 
tissue and lymph nodes.
Results: Thirty-four treatment-naive patients with early or locally advanced HER2-positive BC were 
included in the analysis. The median age of the patients was 49,5 (36-68). Thirteen out of 34 patients (38%) 
were diagnosed in stage II and 21 out of 34 pts (62%) were in stage III. After competition of neoadjuvant 
therapy, thirty-two patients underwent surgery, while two patients, due to the lack of response to neoad-
juvant therapy, were treated with radiotherapy. Overall pCR was attained by 18 patients (56%), pCR 62% 
in stage II and pCR 57% in stage III. Tolerability of neoadjuvant chemotherapy with trastuzumab plus 
pertuzumab was generally good, without any patient discontinuing therapy due to toxicity.
Conclusion: pCR rates obtained among our patients are slightly lower than those reported from the 
majority of neoadjuvant studies with chemotherapy plus trastuzumab plus pertuzumab, mostly due to the 
high percentage of locally advanced stage of BC in our patient population. These findings support current 
recommendations of using dual HER2-targeted combination of trastuzumab and pertuzumab with che-
motherapy in neoadjuvant setting for early and locally advanced HER2-positive BC.
Keywords: HER2-positive BC, neoadjuvant therapy, pCR, dual HER2 blockade
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P22 - PATIENT WITH LIVER TUMORE BEFORE AND AFTER  
LIVER TRANSPLANTATION
Domina Kekez1, Borislav Belev2
1Department of Oncology, Division for Gastrointestinal Cancer, University Hospital Centre Zagreb,  
Zagreb, Croatia  
2Department of Oncology, Division of Medical Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
Introduction: Intraahepatic cholangiocarcinoma is generally a contraindication for liver transplanta-
tion, because of aggressive biology of the disease and poor long term prognosis. However, based on recent 
retrospective trials one question inserts itself. Is there a small group of patients with early ICC (tumor 
smaller than 2 cm) that would benefit from liver transplantation? Additional prospective trial are required 
to answer this question.
Case report: In this case report we will show patient, Š.V, born 1960. In February of 2011 patient 
underwent liver transplantation due to HCC. Patient was a long time alcoholic with liver cirrhosis, osteo-
porosis and arterial hypertension. Tumor was initially found on abdominal ultrasound, and diagnosis was 
confirmed by MSCT and high AFP values. Patient was a candidate for liver transplantation according to 
Milan criteria (solitary tumor less than 4cm in diameter, Child Pugh status B, and in good general condi-
tion, ECOG 1). After liver transplantation there was no sign of disease recurrence until August 2017 when 
two suspicious liver lesions were found on abdominal ultrasound. Additional diagnostic tests (MSCT and 
biopsy of liver) confirmed diagnosis of intrahepatal adenocarcinoma. Given the fact that this histology 
was different then primary tumor, additional molecular testing was done, and it was confirmed that sec-
ond malignancy originated in donor liver (tumor tissue had XX chromosome, donor was a female, and 
patient is a male). Our patient was then discussed in MDT, and conclusion was reached that there is no 
indication for second liver transplantation (ICC, multiple tumor lesions). Our patient received systemic 
chemotherapy, 1 st line cisplatin and gemcitabine, 2 nd line 5fu mono, and 3 rd line irinotecan. At this 
moment patient is still alive, has only intrahepatal disease and is in good general condition.
Conclusion: A number of population and observation studies have shown that patients with trans-
planted liver have higher incidence of secondary malignancies, primary head and neck tumors, esopha-
geal tumors, renal carcinomas and colorectal carcinomas. This fact is probably due to the immunosupres-
sion of these patients. In spite of all protocolar criteria for liver transplantation, there is always a risk of 
occult tumor in transplanted organ, which might become a new disease in patient on immunosupressive 
treatment.
Keywords: hepatocellular carcinoma, cholangicellular carcinoma, liver transplantation
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P23 - PATTERNS OF LOCOREGIONAL RECURRENCE AFTER SURGERY  
AND RADIOTHERAPY OR CHEMORADIATION FOR SQUAMOCELLULAR 
HEAD AND NECK CANCER
Marija Milosavljević, Suzana Matković, Nada Babović, Tamara Ursulović
Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Background: Worldwide, head and neck squamous cell cancer (HNCSCC) are the sixth most com-
mon type of cancer. In Serbia, the incidence of oropharynx,oral cavity, hypopharynx and larynx cancer 
was estimated to 2000 new cases yearly. For patients diagnosed with HNSCC definitive treatment strate-
gies consist of surgery upfornt followed by adjuvant radiotherapy with or without chemotherapy as indi-
cated or chemoradiotherapy for patients with locally advanced head and neck cancer.
Patients and methods: This retrospective study included 20 patients with recurrent or metastatic 
HNSCC who had been treated in Institute for Oncology and Radiology of Serbia, Department of Medical 
Oncology, Department for Head and Neck tumors during the period from January 2019 to February 2021. 
Data were collected from medical documentation.
Results: Median age was 64 years (range 47-76 years) and all patients are men. Laryngeal cancer 
being the most common primary tumor manifestation in 50% and more than two thirds had stage III and 
IVA/B disease. Histologically, all of the treated tumors were squamous cell carcinoma. In the primary 
approach two patients were treated only with radiation therapy, 8 patients had upfront surgery with adju-
vant radiotherapy, 6 patients received neoadjuvant chemotherapy (out of which 4 received with concomi-
tant chemo), 2 received radiation therapy potentiation with weekly cisplatin and 2 with cetuximab. The 
majority of patients were, furthermore, treated with conventional radiotherapy (median 60 Gy, range 
58-70 Gy) in daily fractions of 2 Gy. The median time to recurrence was 10 months (range 3-35). Among 
these 20 patients there were 11 local, 17 regional and 6 simultaneous local and regional recurrences, syn-
chronous distant metastases occured in 3 out of 20 patients. One patient developed distant metastases in 
the absence of a locoregional recurrence. All of the patients received-platinum based chemotherapy with 
cetuximab with disease control in 13 out of 20 patients.
Conclusion: The majority of failure treatment for a locoregional advanced HNSCC were regional 
relapses. Improving a locoregional control remains a high priority to identify the patients with a radiation 
resistant tumor subpopulation and underline the rationale for dose escalation to the highest risk for 
relapse.
Keywords: head and neck squamous cell cancer, locoregional recurrence, radiation therapy
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P24 - SIDE EFFECTS OF LHRH ANALOGUES IN THE TREATMENT  
OF EARLY BREAST CANCER PATIENTS: FREQUENCY AND TIMING
Marija Dimitrijević, Ognjen Djurmez, Marina Čalamać, Kristina Šerovic, Jelena Oblaković,  
Ivana Minić, Zoran Tomašević, Ivana Božović-Spasojević
Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Introduction: LHRH analogues (analogues of luteinizing hormone-releasing hormone) stop the signal 
that the body sends to the ovaries to make oestrogen, which causes temporary menopause. LHRH are 
given in adjuvant therapy for early breast cancer, premenopausal patients with hormone receptor positive 
disease based on the risk of relapse (REF vodic St Gallen2021). In hormone receptor negative breast cancer 
patients LHRH analogues are given concomitantly with chemotherapy with intention for fertility preser-
vation.
Methods: Consecutive patients receiving LHRH analogue therapy in Daily Chemotherapy Hospital 
at the Institute for Oncology and Radiology were included in this analysis. We evaluated the frequency of 
symptoms during therapies at different time periods. Symptoms were reported by patients on monthly 
basis using the list of the most frequent side effects of LHRH based on the literature data. Patients were 
divided into 3 groups according to the LHRH therapy duration: 15, 10 and 5 months respectively. We 
evaluated 4 symptoms as the most frequent: hot flashes, night sweats, insomnia and anxiety.
Results: The first group consists of 50 patients with follow up of 15 months, from November 2019to 
April2021. The second group consist of 46 patients with follow up of 10 months, from June 2020 to April 
2021. The third group consists of 25 patients with follow up of5 months, from December 2020 to April 2021. 
In every group median age was 42, age range from 30 to 53. 80% of total number of patients were node 
negative, 22% of patients have a node negative diseases and tumor size less than two centimetres. 10% of 
patients were HR+HER2+ positive and they received adjuvant Herceptin. LHRH analogues were com-
bined with endocrine therapy: in 99,7 % of patients with tamoxifen and 0,3 % with aromatase inhibitors. 
In 47% of patients LHRH treatment were given concomitantly with sequential chemotherapy, anrtacycline 
and taxane based, due to fertility preservation reasons. In the first group of patients, with the longest fol-
low up of 15 months, the most frequent side effects were hot flashes and night sweats been present in 90% 
of patients, while insomnia and anxiety were detected in 46% and 30% of patients respectively. In the 
second group, with the follow up of 10 months, the prevalence of hot flashes was lower seen in 83%, while 
night sweats were detected in 71%, insomnia in 66% and anxiety in 50% of patients. In the third group, 
with shortest follow up of 5 months the most frequent symptoms were hot flashes 92% and night sweats 
80%.Insomnia was reported in 40% and anxiety in 28% of patients. Other symptoms reported by patients 
were the following: headaches 12%, nonspecific abdominal pain 5 %, nausea 2 % and fatigue 2%.None of 
the patients interrupted their treatment due to the side effects.
Conclusion: In this study, a considerable proportion of young women reported as the most frequent 
symptom hot flashes and night sweats in first 5, 10 and 15 months during LHRH treatment been given as 
part of adjuvant endocrine treatment for early breast cancer. Effective treatment to diminish these side 
effects are needed.
Keywords: breast, cancer, side-effects, LHRH
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P25 - SINGLE CENTER EXPERIENCE STUDY WITH PEMBROLIZUMAB  
IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Aleksandar Popović1, Ivan Petković1,3, Aleksandra Dimitrijević1, Stefan Stankov2,  
Ivica Pejčić1,3, Svetislav Vrbić1,3
1Clinic of Oncology, University Clinical Center Niš, Niš, Serbia  
2Faculty of Medicine, University of Niš, Niš, Serbia  
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Until the introduction of novel agents, the prognosis of metastatic melanoma patients was poor. The 
first registered drug was BRAF inhibitor Vemurafenib in 2011, and since then palette of single and double 
agent therapeutics has been approved. Pillars of treatment nowadays are immune checkpoint inhibitors 
(PD-1 and CTLA-4) in both BRAF mutant and wild type melanoma patients, whereas in BRAF mutant mela-
nomas combined targeted therapy (BRAF and MEK inhibitors) is a possible choice as the first line of treat-
ment. We conducted a retrospective study among unresectable and metastatic melanoma patients treated 
with Pembrolizumab in University Clinical Center Nis from February 2017 to March 2021. We assessed the 
efficacy of Pembrolizumab in general, and among specific subgroups, the appearance of immune-related 
adverse events (irAEs), and also the appearance of irAEs as a predictive factor of prolonged response in the 
real clinical setting. Pembrolizumab efficacy was assessed through overall response rate (ORR) and progres-
sion-free survival (PFS), and toxicity with irAEs. A total of 63 patients, 44 male and 19 female, were included. 
The median age was 64 years. Most of the patients were treatment-naive (84.1%), but patients who received 
single-agent or combined targeted treatment in the first line, were also included. Patients were staged accord-
ing to the AJCC 8th edition staging system. Almost half of the patients were M1c clinical stage (49.2%), fol-
lowed by M1d (28.5), M1a (9.5%), and only one patient was CS III (1.6%). Elevated LDH level was observed 
in 57% of patients. As for the BRAF mutation status 17 patients (27%) had V600E mutation, 9 of them were 
treatment-naive and 8 previously received targeted therapy. A total number of administered cycles was 729, 
with an average of 11.5 cycles per patient. Among all 63 treated patients, 8 achieved complete response (CR, 
12.7%), 9 partial remission(PR, 14.3%), and 19 stabile disease (SD, 30.2%), for a disease control rate (DCR) of 
57.2%. The median time to response was 6 months (range, 2-8 months), and the median time to progression 
was between the 3rd and 4th cycle. At data cut off 29 patients (46%) were still receiving treatment, while 34 
patients (54%) were discontinued due to disease progression (PD, n = 27, 42.9%), adverse events (n = 2, 
3.17%), patient withdrawal (n = 3, 4.77%) or lost to follow-up (n = 2, 3.17%). Among the patients treated with 
Pembrolizumab 14 of them (22.2%) developed Immune-Related Adverse Events (irAEs). There were two 
therapy discontinuations due to recurrent grade III irAE in form of pemphigoid skin rash and grade III auto-
immune hepatitis. Interestingly, seven out of nine patients that achieved complete response had irAEs dur-
ing their course of treatment. As for the efficacy of Pembrolizumab ORR was 44.5%, with a median PFS of 33 
months (CI 95%) achieved. There was no statistical difference among genders, but there was a statistically 
significant difference between treatment-naive and previously treated patients (p=0.002). There was also a 
statistically significant difference in PFS between patients with and without elevated levels of LDH (p=0.05). 
In conclusion, we observed a median PFS of 33 months which endorses long term response which is one of 
the main characteristics of immune checkpoint inhibitors. As for the subgroups, statistically significantly 
lower median PFS was observed among previously treated patients (p=0.002) and patients with elevated 
levels of LDH (p=0.05). Pembrolizumab showed a favorable safety profile, with only 3% high-grade irAEs 
which lead to discontinuation of treatment and also the resolution of symptoms.
Keywords: immunotherapy, advanced melanoma, real world data, adverse events.
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P26 - THE MODEL OF A DIRECT COLLABORATION BETWEEN 
MULTIDISCIPLINARY TUMOR BOARD AND SUPPORTIVE CARE 
DEPARTMENT FOR PATIENTS WITH ADVANCED CANCER
Fedja Djordjević, Jelena Dimitrijević, Marina Čalamać, Ana Žilić, Nataša Lazin,  
Snežana Šušnjar, Vesna Stanković, Snežana Bošnjak
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Introduction: Symptom burden as a result of cancer and its treatment is present across all disease 
types, stages and phases of care in cancer patients. Symptom management guided by patient’s self-report 
of symptoms improves symptom management, quality of life and prolongs overall survival. The Edmon-
ton Symptom Assessment System (ESAS) has been proposed as a screening tool in cancer patients and in 
the clinical setting, ESAS is most often used to identify patient’s unmet needs by systematic screening. It 
consists of 11-point numerical rating scales (0-10) for self-report of nine common symptoms of cancer, with 
a 10th scale for a patient-specific symptom. Each symptom is assessed separately on a scale from 0 to 10, 
with 10 representing the greatest severity. Scores between 4 to 6 correspond to “moderate” symptoms, and 
scores between 7 to 10 reflect “severe” symptom burden. The goal of our study is to evaluate the model of 
a direct collaboration between multidisciplinary tumor board (MTB) and supportive care department 
(SCD) for patients with advanced cancer.
Methods: From November 2018 to December 2019, MTB referred advanced cancer patients with 
severe symptom burden to the SCD. ESAS was used to assess the symptom burden, and severity of symp-
toms was evaluated initially and after the SCD intervention. Assessment of symptom burden after the SCD 
intervention was scheduled 7 days after the initial visit. Descriptive statistics were used to evaluate fre-
quencies, means and/or medians, and standard deviations (SDs) and/or ranges for patient’s demographic 
and clinical information.
Results: ESAS records were collected from 54 patients with median age of 65 years (range 35 -85 
years). Data were collected form 57.4 % female patients and 42.6 % male patients. The most common can-
cer type was genitourinary cancer (27.7%), followed by gastrointestinal (24.07%) and breast carcinoma 
(14.81%) while 11.1 % of patients had a cancer of unknown primary site. The most frequent patient perfor-
mance status (PS), estimated by MTB, was 2 (31.48%) followed by PS 1 (29.6%) and PS 3 (27.7%). Moderate 
to severe pain and moderately to severely impaired well-being were most frequently reported symptoms 
(n=45, 83%, n=29, 53.7%, respectively). Severe nausea, loss of appetite, shortness of breath, fatigue, depres-
sion, drowsiness and anxiety were reported in 5.56%, 33.33%, 7.14%, 42.59%, 25.93%, 16.67%, 31.48% of 
patients, respectively. After seven days clinically meaningful (≤30%) pain relief and improvement of well-
being was reported in 34 patients (62.9%) and 32 patients (59.25%), respectively.
Conclusions: Pain was the most frequent reason for referral from MTB to SCD. Among symptoms 
impaired well-being and pain were most frequently reported symptoms at the time of assessment by the 
supportive care team with the clinically meaningful improvement after SCD intervention. For advanced 
cancer patients with heavy symptom burden the direct collaboration between MTB and supportive care 
team can provide better symptom management and help to better assess and characterize symptom bur-
den as well as to provide timely symptom management at the moment of presentation to the MTB. We are 
conducting further research to examine the impact of ESAS in the treatment decision-making process in 
advanced cancer patients.
Keywords:  patients reported outcomes, Edmonton Symptom Assessment System (ESAS), advanced 
cancer patients
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P27 - TOLERABILITY OF OLAPARIB IN PATIENTS WITH BRCA 1/2-MUTATED 
PLATINUM-SENSITIVE RECURRENT HIGH-GRADE SEROUS OVARIAN 
CANCER RECEIVING OLAPARIB MAINTENANCE MONOTHERAPY:  
A SINGLE INSTITUTION EXPERIENCE
Lidija Pavlović, Simonida Bobic, Andjela Karaferić, Marijana Milović-Kovačević, Ljiljana Stamatović
Instute for Oncology and Radiology of Serbia, Belgrade, Serbia
Background: Olaparib, a poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor, is 
approved in the maintenance setting for patients with platinum-sensitive relapsed ovarian cancer (who 
are in complete or partial response) with germline or somatic BRCA1 and BRCA2 mutations. Safety data 
from clinical trials in recurrent ovarian cancer (OC) patients have shown that olaparib monotherapy is 
generally well tolerated.
Aim: The aim of our study was to investigate the toxicity profile of olaparib used in daily clinical 
practice among patients with recurrent OC.
Methods: At our Medical Oncology Department, patients with BRCA-mutated recurrent OC received 
olaparib as maintenance monotherapy following response to platinum-based chemotherapy (800 mg 
daily, capsule formulation) from November 2019 to February 2021. Adverse events (AE) were closely 
monitored and recorded at least monthly, and graded according to CTCAE v.5.0.
Results: Sixteen patients were included in the study, median age 52.6 (39-63 age). Patients were strat-
ified according to ECOG performance status: 5 pts (31.2%) were ECOG 0 and 11 pts (68.7%) were ECOG 1. 
The majority of adverse events had early onset, usually recorded within the first 3-6 months of drug 
administration. Registered toxicity was as follows: five pts (31,25%) had anemia gr 1, three pts (18,75%) 
had anemia gr 2, seven pts had anemia gr 3 (43,75%), three pts had thrombocytopenia gr 2 (18,75%) and 
three pts experienced neutopenia gr 2 (43,75%), Furthermore, four pts had nausea gr 1 (25%) and five pts 
had fatigue gr 1 (31,25%). One patient discontinued treatment due to prolonged pancytopenia (anemia, 
thrombocytopenia and neutropenia) gr 3/4, but there was no evidence of myelodysplastic syndrome/acute 
myeloid leukemia after a bone marrow biopsy. Due to registered high-grade anemia, the dose of the drug 
was reduced to the 1st level of dose reduction (400mg daily) in seven patients.
Conculusion: Our research showed that olaparib tolerability in platinum-sensitive recurrent OC is 
comparable to previously reported findings in prospective clinical trials. The most frequent high-grade AE 
in our analysis was anemia which was adequately corrected by dose modification and simple supportive 
measures. The most common non-haematological AEs (fatigue, nausea) were mild in severity and did not 
require treatment modification. Patient education and awareness of side effects can also be helpful in man-
aging olaparib toxicity.
Keywords: recurrent BRCA-mutated ovarian cancer, olaparib, toxicity
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Background: The combination of atezolizumab and bevacizumab has been approved globally for 
patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, 
based on results from IMbrave150 (NCT03434379).
Results: At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezoli-
zumab–bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79, 
P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab–bevacizumab 
and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 
5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression 
or death, 0.59, 95% CI, 0.47 to 0.76, P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients 
who received at least one dose of atezolizumab–bevacizumab and in 55.1% of 156 patients who received 
at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab–
bevacizumab group, however, other high-grade toxic effects were infrequent.
Case report: A 62-year-old woman with a 4-month history of jaundice, dark urine and pale stools was 
presented to her family doctor in September 2019. She gave no history of chronic medical illnesses, there 
was no drug or allergy history of note. She had a positive family history of lung and brain cancer. The 
patient was a long-term smoker who has stopped smoking since the symptoms started. A Multi-Slice 
Computed Tomography (MSCT) of the abdomen showed inhomogeneous and unsharply marked tumor 
in the right lobe (segment V and VI) of liver, with a diameter of 5.5x7 cm. The patient was taken up for 
surgery in October 2019. She underwent a right hepatectomy, cholecystectomy, left hepaticojejunostomy 
and radical lymphadenectomy. Histopathology report showed HCC. Postoperative recovery was unevent-
ful. She was seen in our oncology clinic for further management. Postoperative Magnetic Resonance Imag-
ing (MRI) of the abdomen showed multiple hepatic satellite lesions (segment II-1.6x1.2 cm, segment IVa-
1.2 cm, segment IVb-1.3 cm, with a few minor lesions in the remaining liver segments). Postoperative 
serum alpha-fetoprotein (AFP) level was 13.1 ng/ml. In February 2020 patient started treatment with a 
combination therapy of the atezolizumab (1200 mg iv) and bevacizumab (15 mg/kg iv) every 21 days. In 
April 2020, the tumor response was evaluated according to the modified Response Evaluation Criteria in 
Solid Tumors, and a complete response (CR) was identified. MRI of the abdomen showed complete regres-
sion of previously visible metastatic liver lesions. The serum levels of AFP decresead from 13.1 to 3.2 ng/
ml. She continued to receive atezolizumab and bevacizumab combination therapy. Manageable toxicity 
included grade 2 hypertension and grade IA hypothyroidism. Until now, the patient received a total of 20 
cycles of combination therapy and she had maintained CR.
Conclusions: IMbrave150 trial showed consistent clinically meaningful treatment benefit and safety 
with 12 months of additional follow-up. The combination provides the longest survival seen in a front-line 
Phase III study in advanced HCC, confirming atezolizumab and bevacizumab combination as a standard 
of care for previously untreated, unresectable HCC.
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P29 - YOUNG-ONSET COLORETAL CANCER
Neda Nikolić, Nemanja Stanić, Jelena Spasić, Vladimir Nikolić, Feđa Đorđević, Davorin Radosavljević
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Background: In contrast to the decreasing incidence of colorectal cancer (CRC) in older populations, 
the incidence in younger adults has nearly doubled since the early 1990s. Increasing incidence of early-
onset colorectal cancer is poorly understood and rising number of publication is trying to describe its 
clinical characteristics, pathogenesis, genetic background and potential risk factors. Differences in clinical 
behavior and tumor phenotypes have been observed, suggesting that early-onset CRC could be a different 
disease than the traditional CRC.
Methods: The records of patients with histologically confirmed colorectal carcinoma bellow 40 years 
of age at the time of diagnosis treated in a ten year period (between 2009 and 2018) at single institution 
were reviewed. Clinical and histopathology data were evaluated.
Results: In a 10 year period, 109 patients with colorectal cancer, younger than 40 years of age at the 
time of diagnosis have been treated at single institution (2.7% of all-age patients with diagnosed CRC). 
Median age was 35 (range 19-40), 49% were female, PS0 in 66.1%, PS0+1 in 98% of patients. Patient had 
mostly normal BMI (49.3%). Family history was positive for various malignancies in 26.6% cases with fam-
ily history positive for colorectal cancer in 12.8% patients. Most of the patients experienced some disease 
specific symptoms, having one symptom in 55.9% patients and two or more symptoms in 37%. Acute 
bowel obstruction was a presenting symptom in 35% of patients with tumor perforation registered in 
6.4%. There have been 57% of colon cancer and 46% of rectal cancer. Sigmoid carcinoma was most often 
diagnosed among patient with colon carcinoma (45.6%). Disease was mostly localized in a left colon, in 
83.5% of patients. Mucinous tumors were diagnosed in 25.7% of patients. Initially patient were diagnosed 
in stage II, III and IV in 18.3%, 47.7% and 33.9%, respectively.
Conclusions: Colorectal cancer should no longer be considered a disease of older people. Patient 
have presenting symptoms, with high percentage of acute one. These tumors have a striking predilection 
for distal colon, particularly the sigmoid colon and rectum and are much more likely to demonstrate 
adverse factors, including mucinous differentiation and advanced disease.
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